- 08:24 AM Market cues: FIIs net sell $14.6 mn
- 08:20 AM F&O cues: Total Futures Open Int up by Rs 982 cror...
- 08:16 AM Asia trading firm; Shanghai Composite, Hang Seng u...
- 08:12 AM Nifty likely to witness range of 5130-5050: Bhambw...
- 08:09 AM Support for Sensex at 17050: Gaba
- 08:01 AM Nifty has support at 4960-5000: Gujral
- 07:56 AM Indian ADRs: ICICI Bank, Satyam down, Tata Comm up
- 07:52 AM US mkts off days low after Fed raised 2010 GDP for...
- 07:22 AM India and US agree on new economic partnership
- 10:42 PM Are stricter rules for MF advertisements on anvil?



GlaxoSmithkline Pharma may strike a sourcing deal with Cipla for inhalation devices. It is learnt that the two companies are holding discussions that may benefit both, reports CNBC-TV18.
It looks like tradtional rivals GlaxoSmithkline Pharma and Cipla are forging a closer bonding. GlaxoSmithkline is believed to be in discussions to source inhlation devices from Cipla for Asia.
And though Cipla chose not to comment, Glaxo officials maintained that the news is speculative but the company works with partners keeping in mind specific local manufacturing advantages.
Analysts say the sourcing deal works well for both the companies. While GlaxoSmithkline has a clear dominance over the world market for respiratory products, Cipla has been making a steady headway in devices such as aerosols.
Interestingly, while Cipla ranks as the top drugmaker in the domestic market, GlaxoSmithkline ranks third with an almost similar product basket as that of Cipla.
The two companies compete in various segments including respiratory drugs, anti-infectives, anti-aids drugs and drugs for chronic diseases such as diabetes and vardiovascular ailments.
Cipla is known globally for its inhalation products manufactured at cheap costs and Glaxo's compulsions to cut costs for its own products may get the two rivals work closely.
Cipla is in preliminary talks with Reliance Retail for outsourcing the products.
When approached, Cipla refused to comment and Glaxo UK said the news is speculative.
Disclaimer: This information is source-based and has not been provided to the stock exchanges.
|
|
Business
Business News | Economy | Earnings | BSE NSE Notices
General News
Current Affairs | Politics | World News | Sports | Entertainment
Corporate Strategy
Management | Advertising | Marketing | Legal
Personal Finance
Tax | Insurance | Credit Cards | Loans | Property | Retirement | Investment Help | Financial Planning | Fixed Income
Markets
Local Market | Global Market | Market Cues | Analysis | Expert & FII outlook | Brokerage Recomendation
Stocks
Stocks in News | Expert Advice | ADRs & GDRs | IPO
Mutual Funds
News | Advice | MF Analysis | Fund Managers Views
Lifestyle
Travel | Wellness | Technology | Auto| Books
-
Most Read
-
Most Viewed
- 10 Companies that FIIs love
- 10 companies that MF managers love
- Expert sector picks to power your portfolio ahead

- Will ITC dream run continue beyond FY10?

- Mitesh Thacker's top 5 picks for trade today

- Moody's maintains negative view on India's credit condition

- Bollywood actress Shilpa Shetty marries Raj Kundra
- Den Networks closes 16% lower on first day
- Worst over for India auto companies: Anand Mahindra
- India indispensable to America's future: Barack Obama
- Mahindra may increase car prices due to rising input costs
Source: Business Line
- Renault to continue with M&M for Logan, says Ghosn
Source: Business Line
- Market volatility poses valuation problems: IRDA
Source: Business Line
- Punjab, Haryana buck all-India rice decline trend
Source: Business Line










